Conference Coverage
Latest News
Jun 25, 2026 | Opinion
Isaac Kim, MD, discusses the future of immunotherapy in prostate cancer
NCCN recommends ctDNA-MRD testing to guide adjuvant treatment post-cystectomy
Jun 24, 2026
Real-time cavitation monitoring drives Break Wave's renal hematoma safety advantage
Jun 24, 2026
European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC
Jun 24, 2026
Fred Saad, MD, highlights PSA end points from the phase 3 PSMAddition trial
Jun 24, 2026
Advertisement
Shorts
0:58
Heat, plastic, and exposure: What patients should know
2 hours ago
by
Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES
0:52
Vivian Wan, MD, on the value of mapping biopsies for CIS detection
2 days ago
by
Vivian Wan, MD
1:12
FDA testosterone label updates: 2 meaningful changes
3 days ago
by
Helen L. Bernie, DO, MPH
0:36
EV-302 response rates put surgical consolidation in context
6 days ago
by
Betty Wang, MD
0:52
Amy E. Krambeck, MD, outlines anatomic enucleation course
7 days ago
by
Amy E. Krambeck, MD
1:23
Daniel J. George, MD, on the significance of capivasertib for PTEN-deficient mHSPC
8 days ago
by
Daniel J. George, MD
1:43
What it takes to move the needle on urologic patient safety
9 days ago
by
Matthew Nielsen, MD, MS, FACS
0:42
Why patients choose Break Wave over URS
10 days ago
by
Ben H. Chew, MD, MSc
0:36
Jenny N. Guo, MD, on key BPH takeaways from AUA 2026
14 days ago
by
Jenny N. Guo, MD
0:44
Joy Maulik, CRNP, highlights LUGPA Advanced Practice Provider Forum
15 days ago
by
Joy Maulik, CRNP
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Mina M. Fam, MD, discusses the significance of the FDA's recent approval of tebipenem pivoxil for patients with complicated urinary tract infections.
Enzalutamide plus talazoparib showed promising clinical activity in high-volume mHSPC, although with a notable toxicity burden.
In this episode of Pearls & Perspectives, host Amy Pearlman, MD, is joined by Larry Lipshultz, MD, and Rachel Rubin, MD, for a conversation on advocacy, sexual medicine, and the evolving role of urologists in women’s health.
Rahul Winayak, MD, discusses the prognostic and predictive value of microbial dysbiosis in patients receiving CBM588 plus first-line immune checkpoint inhibitor-based regimens for metastatic renal cell carcinoma.
Eugene Pietzak, MD, highlights results from a phase 2 study of pembrolizumab plus BCG for patients with very high-risk, BCG-naive high-grade T1 NMIBC who declined upfront radical cystectomy.
Preston C. Sprenkle, MD, discusses the unmet needs, emerging solutions, and longer-term vision for MRI in prostate cancer care.
Unwanaobong Nseyo, MD, MHS, discusses a retrospective analysis comparing treatment continuation outcomes with minimally invasive therapies for idiopathic overactive bladder.
Sandip Prasad, MD, discusses 3-year data from the phase 3 ENVISION trial evaluating mitomycin for intravesical solution for recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.
In this episode of The UroOnc Minute, Lourdes Guerrios-Rivera, MD, discusses strategies to improve patient engagement and adherence during active surveillance for prostate cancer, highlighting the critical roles of education, communication, and structured follow-up.
The agency is requesting a removal of the limitation of use for age-related hypogonadism as well as updated warnings related to prostate cancer risk and benign prostatic hyperplasia.
Advertisement
Data from the RAMPART trial showed that durvalumab monotherapy missed the DFS threshold in resected RCC, though the combination with tremelimumab showed significant benefit.
Andrew J. Armstrong, MD, MSc, discusses efficacy results from a phase 2 study evaluating a chemoimmunotherapy regimen for patients with neuroendocrine or aggressive-variant metastatic prostate cancer.
The prospective RELIEF study will evaluate the safety and preliminary efficacy of IRE delivered via the NanoKnife System for BPH-related symptoms.
In this episode of Pearls & Perspectives, Thomas F. Stringer, MD, FACS, discusses his journey from private practice to academic urology, his priorities as incoming AUA president, and opportunities to improve men's health engagement and education.
The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin.
Advertisement
Advertisement
Trending on Urology Times
1
NCCN recommends ctDNA-MRD testing to guide adjuvant treatment post-cystectomy
2
European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC
3
Lymph Node Dissection Following Systemic Therapy in MIBC
4
Fred Saad, MD, highlights PSA end points from the phase 3 PSMAddition trial
5